ARCHIVES

Legacy CEO Cheryl Healton says foundation could serve as funder for research on “potentially reduced-exposure products.”

This article is from The Cancer Letter archive.

Vol. 30 No. 41 | October 29, 2004

Download PDF Visit The Full Archive

Related Articles

“We’d Ban Cigarettes’ If Nicotine Were a Drug, FDA Commissioners Says

February 14, 1992

Phase III Avastin Trial Fails Primary Endpoints

February 28, 2014

FDA Publishes Two Guidances for Lab-Developed Tests

October 3, 2014

ACS Expresses Concern About “Fletcher Report” On Mammography

May 7, 1993

Phase III Trial Data: Lenvatinib Extends PFS by Over 14 Months

June 27, 2014

NLMs Grateful MED Aids Data Searches

March 21, 1986